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 Apolipoprotein E (APOE) interacts with the lipoprotein receptor to transport lipoproteins 
and facilitates ingestion of apoptotic cells, also known as efferocytosis. APOE-deficient 
macrophages ingest fewer apoptotic cells than wildtype cells. Because apoptotic cells are found 
in lesions of demyelination, we speculated that APOE and efferocytosis may be involved in 
remyelination. Our hypothesis is that APOE regulates OPC differentiation via the microglia 
secretome. To test this hypothesis, we assessed remyelination in vivo using APOE-/-, APOE2, 
APOE3, and APOE4 knock-in mice and in vitro using the OPC differentiation assay. In vivo, we 
found APOE3 mice showed delayed remyelination at the 5+2 week time point, but by 5+3 week 
the APOE3 variant was similar to WT. This indicates that APOE3 partly inhibits the 
remyelination process. Furthermore, it was found that APOE-/- had significantly more 
remyelination than other genotypes at the 5+1 time point, which suggests murine APOE inhibits 
remyelination temporarily. In vitro, the OPC differentiation assay showed that APOE3 and 
APOE-/- macrophage secretomes retained significantly more round and primary processes than 
the positive control indicating there were less factors driving initial cell differentiation. This 
suggests that murine APOE is required for efferocytosis and secretome content, but APOE3 
may inhibit efferocytosis and alter the beneficial factors for OPC differentiation. 
 
Introduction: 
Multiple sclerosis (MS) is a demyelinationing disease of the central nervous system that 
affects 350,000 people in the United States. In higher risk regions of the world such as North 
America and Northern Europe, approximately 60-200 out every 100,000 people have MS, while 
in countries with relatively low risk, such as Japan, 6-20 people in 100,000 are affected 
(Sospedra, 2005). The disease causes a variety of disabilities ranging from problems with 
sensation and motor function to autonomic and neurocognitive issues. There are three general 
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presentations of MS: relapsing-remitting, secondary progressive stage, and primary-progressive 
MS (Sospedra, 2005).  
MS results from the demyelination of axons, which impedes electrical impulse 
conduction and trophic and metabolic support. However, it has been shown that these effects 
can be reversed through axon remyelination (Lloyd, 2019). Microglia, the macrophages of the 
brain, have a central role in the remyelination process. They are involved in a variety of brain 
functions, including promoting development, maintaining homeostasis, and responding to brain 
infections and damage. While microglia both protect the brain and promote regeneration, they 
can also have damaging effects on the brain through the promotion of inflammation. Early in 
embryonic development, precursor myeloid cells migrate to the neuroectoderm, where they 
become microglia of the brain (Lannes, 2017). After birth, microglia support the differentiation of 
oligodendrocytes (the cells that myelinate axons) and myelination (Hamilton, 1994). Additionally, 
they help support regions of the brain that contain myelinated axons by “maintain[ing] 
oligodendrocyte progenitor numbers in the adult healthy brain” (Hagemeyer, 2017). In 
demyelinated lesions, the myelin debris inhibits remyelination (Kotter, 2006). How microglia 
support remyelination is partly unknown. However, it has been found that microglia support 
myelin repair by phagocytosing myelin debris (Triarhou, 1985), secreting various growth factors 
and cytokines (Dillenburg, 2018; Pasquini, 2011; Mason, 2001), and clearing cholesterol via the 
protein APOE (Cantuti-Castelvetri, 2018). Interestingly, it has been found that, in older mice, 
both myelin debris and cholesterol crystals accumulate in demyelinated lesions and this 
phenotype can be induced experimentally by knocking out the apoe genes (Cantuti-Castelvetri, 
2018).  
 APOE is a 34-kDa glycoprotein with 299 amino acids (Shore, 1973). There are three 
human variants of this protein: APOE2, APOE3, and APOE4 (Mayley, 2008). APOE3 is the 
most common of these variants with an allele frequency of 65-70% (Zannis, 1982). Both APOE2 
and APOE4 differ from APOE3 at one of two amino acid positions. APOE3 has Cys-112 and 
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Arg-158, while APOE4 has an amino substitution at position 112 for arginine and APOE2 has an 
amino acid substitution at 158 for cysteine (Mahley, 2008). The APOE4 protein has been 
associated with an increased risk for coronary heart disease as well as Alzheimer’s disease 
(Utermann, 1984). Additionally, if an individual with HIV is homozygous for APOE4, their AIDs 
will progress at a faster rate (Burt, 2008). On the other hand, APOE2 has been found to be 
overrepresented in octogenarians, (i.e. people between the ages of 80-89), so it is thought to 
influence longevity (Schächter, 1994). Due to structural differences between APOE3 and 
APOE2, APOE2 has a defective LDL-receptor binding site (Mahley, 2008). These three variants 
illustrate how a small change in protein sequence can drastically affect the function of APOE.  
 APOE is involved in lipoprotein transport by clearing triglycerides and cholesterol-rich 
lipoproteins. It does this by interacting with the low-density lipoprotein receptor. It has been 
found that the deletion of the apoe gene in apoe-/- mice results in the failure to clear lipoproteins 
from the blood (Moghadasian, 2001). APOE also has an effect on macrophages’ ability to 
efferocytose (Grainger, 2004). In vitro, it has been found that apoe-/- macrophages phagocytose 
fewer apoptotic cells than their wildtype (WT) control. However, when APOE is reintroduced to 
these macrophages, this problem is corrected.  Additionally, WT macrophages ingest fewer 
apoptotic thymocyte cells when these thymocytes were apoe-/- mice (Grainger). And even fewer 
were ingested when both the apoptotic cells and macrophages were both derived from apoe-/- 
mice (Grainger, 2004). This suggest that APOE may play a role in facilitating efferocytosis. 
Grainger, et al. also investigated the effects of apoe in vivo and found that in apoe-/- mice, there 
were more dead macrophages than in WT mice. They believe this may be because more 
macrophages were recruited due to less apoptotic cells being cleared (Grainger, 2004). It is 
likely that fewer apoptotic cells were cleared due to decreased efferocytosis by apoe-/- 
macrophages (Grainger, 2004). They also found that the proinflammatory cytokine TNF-alpha 
and fibrinogen, a positive acute phase reactant, were elevated in the liver in apoe-/- mice. None 
of these effects were seen if the gene for the LDL receptor was deleted or if mice were fed a 
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high cholesterol diets (Grainger, 2004). This indicates that APOE’s interaction with the LDL 
receptor in lipoprotein metabolism is independent of APOE’s effects on the number of 
macrophages and apoptotic cell uptake (Grainger, 2004). Thus, APOE could be regulating local 
inflammation by suppressing the function of macrophages. Although it is not well understood 
how the lack of APOE in the brain affects the ability of macrophages to function efficiently, some 
suggestions have been made (Grainger, 2004). Grainger et al. posits that it could be indirectly 
affecting macrophage uptake levels by changing the expression of certain factors that are 
necessary for apoptotic cell clearance or by affecting Mertk expression, which is a key receptor 
for apoptotic cell clearance (Grainger, 2004). Thus, if APOE were to interact with Mertk, then 
efferocytosis may either be enhanced or it may be hindered.  
I am studying how APOE may promote or interfere with the process of remyelination. 
Our hypothesis is that APOE regulates OPC differentiation via apoptotic cell-stimulated 
macrophage or microglia secretome. By regulating OPC differentiation, APOE would promote or 
inhibit the remyelination of axons. To test this hypothesis, we conducted both in vivo and in vitro 
assays with apoe2, apoe3, and apoe4 knock-in and apoe-/- mice using OPC differentiation 
assays and the cuprizone model of demyelination and remyelination. The in vivo assay takes 
sections of the brain to investigate their level of remyelination at different weekly time points 
(See Figure 1 for cuprizone time course of demyelination and remyelination). We plan to assess 
remyelination in the apoe mice to determine whether repair is similar to or delayed when 
compared to the time course of our standard WT (C57BL/6J) mice. 
The in vitro OPC differentiation assay quantifies the extent of morphological processes 
of isolated OPCs after exposure to various apoe macrophage supernatants. Data from the lab 
conducted previously indicated that macrophages from apoe3 mice were deficient in 
efferocytosis whereas apoe2 and apoe4 macrophages ingests apoptotic cells similarly to WT 
macrophages. This suggests that the supernatants from apoe3 macrophages may have a 
different composition of secreted factors and the altered secretome could have reduced effects 
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on OPC differentiation. Here, we plan to assess whether supernatants from apoptotic cell-
stimulated apoe3 macrophages can induce OPC differentiation. This may provide insights that 




C57BL/6J mice served as WT mice that were bred and maintained in our colony under 
IACUC-approved protocols. apoe2, apoe3, apoe4, and apoe-/- mice were previously bred onto 
the C57BL/6J background and obtained from Dr. Nobuyo Maeda. Mice were bred and 
maintained for 8 weeks before exposure to 0.2% cuprizone treatment and for in vitro 
experiments. 
 
Sectioning/ Luxol fast blue (LFB) and periodic acid Schiff’s base (PAS) staining: 
Brains used for myelin staining were extracted from 4% paraformaldehyde (PFA) 
perfused animals, gross cut to isolate the midbrain, post-fixed in 4% PFA for 3-4 hours, and 
transferred to 30% sucrose for over-night cryoprotection. Brains were mounted in OCT the 
following day and stored in -80˚C freezer until sectioned. A cryostat was used to cut the brains 
into 5-μm coronal sections that displayed the corpus callosum and fornix and mounted onto 
glass slides. This analysis was conducted on three sections that were at least 30 micrometers 
away from each other to obtain a relative representation across the length of the corpus 
callosum above the fornix. To examine how much of the corpus callosum was myelinated, 
coronal brain sections were stained with LFB-PAS. The LFB stains myelin in the brain blue, 
while the PAS base stains demyelinated axons pink. On day one, the brain sections on slides 
were rinsed in PBS and dehydrated in 70%, 80%, and 90% ethanol. Then, the slides were put 
into LFB solution and baked overnight at 60˚C. On the second day, the slides were allowed to 
cool and were rinsed with 80% ethanol and dH2O. The slides were dipped into 0.05 % LiCO3, 
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70% ethanol, and rinsed in dH2O to remove excess LFB. The decoloration of each slide was 
analyzed under the microscope. Once the brain sections were properly stained blue, the slides 
were oxidized in 1% periodic acid for 5 minutes and then rinsed in dH2O. Next, the slides were 
placed into Schiff’s reagent for 10 minutes and washed under running tap water. Finally, the 
slides were decolorized in 0.25% acid alcohol, rinsed with H2O, and mounted in resin. The 
myelination of the corpus callosum was scored by a blind observer with a didymium filter using 
x200-600 magnification with an Olympus BX-40 microscope. The scores ranged from 0-3, 
where 0 is completely unmyelinated and 3 is completely myelinated. Increments of 0.25 were 
used for intermediate scores of partial myelination (Doan, 2012). The LFB staining protocol was 
developed by previous lab member Lorelei Taylor who modified it from Elise Cash. 
 
OPC differentiation assay: 
The protocol for culturing, enriching, and isolating the mice oligodendrocyte precursor 
cells (OPCs) was developed by the Matsushima lab prior to this project and were based on 
modified methods described by Yang et al, 2016 and Niu et. al, 2012. Two new media reagents 
were adopted: Modified Growth Media or mOGM (DMEM/F12 + 1% N2 Supplement + 1% B27 
Supplement + 5μg/mL insulin + 10ng/mL PDGF + 10ng/mL FGF + 1% PEN STREP) and 
Modified Isolation Media or mOIM (DMEM/F12 + 0.004% EDTA + 0.5% DNase I + 5μg/mL 
insulin + 1% PEN STREP).  
Mixed glia cells from 3-day old neonatal PLP-eGFP mice mouse pups were cultured in 
DMEM and 10% FBS media. After four days, the oligospheres were isolated and re-suspended 
in mOGM media, which was replaced every two days. After 2 weeks, the oligospheres were 
removed from the media and dissociated in mOIM. Afterwards, the oligospheres were 
mechanically dissociated and incubated for 20 minutes. This was repeated until a majority of the 
oligospheres were single cells and used as oligodendrocyte progenitor cells (OPCs).  
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The isolated OPCs were then re-suspended in DMEM media at a concentration of 2 x 
105 cells/mL and seeded into a 96-well plate with 25 μL in each well. To this plate, 25 microliters 
of macrophage supernatants were added and the plate was then incubated at 37˚C. Then the 
wells are imaged after 48 and 72 hours. The macrophage supernatants are produced by 
exposing adherent macrophages to apoptotic cells for one hour and then thoroughly washing 
the undigested cells away. The macrophage cultures are then replenished with media without 
phenol red which may stimulate macrophages and without fetal bovine serum that would add 
unwanted cell support factors to the supernatant. After 24 hours, we harvest supernatants and 




Figure 1: Cuprizone model of demyelination and remyelination 
This model (modified from Matsushima and Morell 2001) has strengths in the reliability, 
robustness, and reproducibility of the changes at a restricted location so that time-sensitive 
correlations can be made at the morphologic, cellular and molecular levels. There are four major 
cell types within the heavily myelinated fiber tract: mature oligodendrocytes, oligodendrocyte 
precursor cells during repair, microglia and astrocytes. In the adult, mature oligodendrocytes 
predominate; however, during cuprizone insult, mature oligodendrocytes die by apoptosis and 
this sets in motion a cascade of events including microglia, astrocyte and OPC accumulation 
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where most peak numbers are observed around week 5, full demyelination. Upon remyelination, 
OPCs differentiate and remyelinate the lesion over the next 3 weeks. Remyelination is typically 
complete by week 5+5. Microglia clear apoptotic cells and myelin debris that is thought to be 
inhibitory to remyelination and additionally provide cues for OPCs to mature (Matsushima, 
2001).
Figure 2: LFB-PAS staining suggests that apoe3 mice are delayed in remyelination 
LFB-PAS staining of apoe3 (APOE3 in the figure) mice brains at the 5+2 timepoint shows 
significantly less levels of myelin when compared to the WT and other apoe variants [apoe2 
(APOE2) and apoe4 (APOE4)]. At the 5+1 time point, apoe-/- (APOE-/- in the figure) brains 
exhibited significantly more myelination. At the 5+3 week time point there is no significant 
difference between the levels of myelination. P<.05, **P<.01, ***P<.001, ****P<.0001. N- 
numbers displayed on graph. Statistical significance was obtained by two-way Anova, and 




















Figure 3: OPC differentiation is inhibited by APOE3 macrophage supernatants 
Pictures are taken of the OPCs at 48 (A) and 72 hours (B) post the introduction of the 
macrophage supernatants. A. OPCs treated with APOE3 (E3) macrophage supernatants at 48 
hours had significantly more OPCs with primary processes than those treated with the positive 
and negative control supernatant. Additionally, OPCs treated with APOE3 macrophage 
supernatants had significantly less complex OPCs than those treated with WT (B6), APOE-/- (E 
KO), and the positive control supernatant. B. OPCs treated with APOE3 macrophage 
supernatants at 72 hours had significantly more OPCs without any differentiation than those 
treated with the positive control supernatant. Additionally, OPCs treated with APOE3 
macrophage supernatants had significantly less complex OPCs than those treated with WT (B6) 
and the positive control supernatant. C. At 48 hours, OPCs treated with APOE3 macrophage 
supernatants show significantly less complex than APOE-/- supernatants and the positive 
control. At 72 hours, OPCs treated with APOE3 and APOE-/- macrophage supernatants show 
significantly less complex than the positive control. WT is B6. Negative control: just media, 
Positive control: T3 and db-cAMP. P<.05, **P<.01, ***P<.001, ****P<.0001. Statistical 
C. 
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significance was obtained by two-way Anova, and Bonferroni's multiple comparison test. Data 
collected and analyzed by Isabel Elssner. 
Results: 
 
In vivo assessment using cuprizone model of demyelination and remyelination.  
This model uses cuprizone diet given over a 5-week period to induce full demyelination 
(Figure 1). At week 5, cuprizone feed is replaced with normal chow and spontaneous 
remyelination occurs. Harvesting brains at week 5+1, 5+2 and 5+3 typically allows for the robust 
change in remyelinating fibers. Mice were previously treated with cuprizone and harvested at 
the indicated time points during remyelination. I cut coronal sections of the corpus callosum 
above the fornix and kept them at -80C until their LFB-PAS staining. This region of the corpus 
callosum minimizes variables such as fiber direction and provides robust range in fiber 
myelination for scoring after LFB-PAS staining. 
 
LFB-PAS staining suggests that apoe3 mice are delayed in remyelination. (Figure 2). 
 We know that following full demyelination in mice brains after 5 weeks of cuprizone 
treatment, mice start to undergo remyelination with myelin levels increasing each week following 
the 5 week timepoint. We hypothesize that APOE may inhibit the remyelination process. To test 
this hypothesis, we conduct LFB-PAS staining of the corpus callosum in WT mice, apoe2, 
apoe3, apoe4, and apoe-/- mice. The myelin stains blue by the LFB and the rest of the brain 
stains pink with the PAS. After staining, the corpus callosum sections are scored blindly on a 
scale from 0 (no myelination) to 3 (full myelination). At the 5+1 week time point, apoe-/- brains 
exhibit significantly more myelination than the WT and other apoe variants. WT mice are just 
beginning to remyelinate and scores are relatively lower compared to the apoe-/- mice 
suggesting murine apoe may be inhibitory. There is no change in apoe-/- mice myelination in 
subsequent weeks and there is no difference compared to WT mice as remyelination increases 
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and matches remyelination extent with apoe-/- mice. The mechanism for the inhibitory effect of 
murine APOE is not clear. 
For apoe knock-in mice, remyelination varies significantly. apoe2, apoe3, and apoe4 
mice show similar demyelination at week 5 compare to WT mice (Figure 2). In addition, early 
remyelination at week 5+1 is also similar among the three strains. In contrast, while apoe2, 
apoe4 and WT mice continue to remyelinate, there is a significant delay in remyelination for the 
apoe3 brains at the 5+2 week timepoint. apoe3 mice are nearly half the score (0.75 compared 
to ~1.5) of their counterparts. This lower myelination score by apoe3 mice increases by the 5+3 
week timepoint as there no significant difference in remyelination levels. Therefore, it appears 
the presence of APOE3 may be inhibitory and causes a temporary delay in remyelination. 
 
OPC differentiation is inhibited by apoe3 macrophage supernatants (Figure 3). 
Oligodendrocyte precursor cells (OPCs) differentiate into mature oligodendrocytes 
capable of myelinating axons. We know that APOE3 inhibits the remyelination process (Figure 
3), so our hypothesis is that APOE3 has an inhibiting effect on oligodendrocyte precursor cells. 
To test this hypothesis in vitro, we isolate OPCs and expose them to supernatants from apoe3 
macrophages stimulated by apoptotic cells. The ability of macrophage supernatants to induce 
OPC differentiation are compared to WT supernatants and T3+db-cAMP positive control wells. 
Negative controls are OPCs with media alone. Pictures are taken of the OPCs at 48 and 72 
hours post the introduction of the macrophage supernatants.  
At 48 hours, apoe3 macrophage supernatants (red bar) show more OPCs in the primary 
state with single processes (Figure 3A). The positive control T3+db-cAMP (black bar) show 
significantly fewer primary cells, nearly half the number, in comparison to apoe3 supernatants 
indicating OPCs are moving towards differentiation. There is no difference among the OPCs in 
the secondary or tertiary phenotypes. Additionally, OPCs treated with APOE3 macrophage 
supernatants had significantly less complex OPCs than those treated with WT (blue bar) APOE-
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/- (orange bar), and the positive control supernatant. At 72 hours, apoe3 macrophage 
supernatants show the most OPCs in the rounded state similar to negative control. (Figure 3B). 
This suggests apoe3 supernatants lack important factors to drive OPC differentiation. In 
contrast, positive control and WT (B6) supernatants show significantly more OPCs in complex 
states and suggests greater movement towards differentiation. 
 At 48 hours (Figure 3C), apoe3 supernatant does not show substantial OPC 
differentiation whereas positive control and unexpectedly apoe-/- show maturation from rounded 
OPCs. When we assess the total scores for each timepoint, it appears the 72 hours may be 
more reliable. The apoe3 supernatants perform poorly when comparing the positive control. 
Similarly, the apoe-/- also show less differentiation that is comparable to the negative control. 
These data suggest apo3 and apoe-/- supernatants do not support late OPC differentiation as 
robustly as the positive control. Therefore, apoe3 supernatants at 48 hours and 72 hours fail to 
support OPC differentiation. Interestingly, apoe-/- supernatants supported early OPC 
differentiation at 48 hours but not at 72 hours. Unfortunately, the WT (B6) macrophage 
supernatant is predicted to be similar to T3+db-cAMP; however, these supernatants did not 
behave as expected possibly due to prior freeze-thaws that may have lowered their active 
factors. The main conclusion is that at 72 hours, OPCs treated with apoe3 and apoe-/- 
macrophage supernatants show significantly less complex processes than the positive control. 
 
Discussion:  
 We speculate that APOE may bind apoptotic cells and either facilitate or hinder 
efferocytosis. We have shown that proper efferocytosis by macrophages may be important for 
secretion of oligodendrocyte precursor cell differentiation. This process may be intercepted by 
APOE and may have consequences to lesion repair. Here, we assessed both in vivo and in vitro 
whether APOE subtypes affect OPC differentiation and remyelination. Our data finds an 
accelerated remyelination in apoe-/- mice at week 5+1 week that is unexpected. It is not clear 
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why it is so high unless there was a technical error in staining. However, our OPC differentiation 
assay shows at 48 hours, apoe-/- macrophage supernatants that OPC differentiation was 
temporarily accelerated. It is plausible that initial factors produced early facilitates OPC 
differentiation in apoe-/- mice; however, we deduce in the presence of APOE, they are 
suppressed or inhibited.  
In contrast, LFB-PAS staining of the corpus callosum of apoe3 mice showed a significant 
delay in myelination at the 5+2 time point when compared to the WT and other apoe variant 
mice. LFB-PAS stain at week 5+3 suggests apoe3 mice recover remyelination similar to WT 
mice. The OPC differentiation assay showed that OPCs treated with apoe3 macrophage 
supernatants for 48 hours were significantly less complex than apoe-/- and the positive control. 
At 72 hours, OPCs treated with apoe3 macrophage supernatants were also significantly less 
complex than the positive control. This suggests that APOE3 may interfere with efferocytosis 
and prevent proper secretome content. Indeed, previous lab experiments suggest macrophages 
from apoe3 mice are defective in efferocytosis (data not shown). We believe that, after clearing 
apoptotic cells, macrophages produce factors that promote OPC differentiation, but APOE3 may 
change the production of these factors.  
In summary, we believe that APOE3 could be interfering with the phagocytosis of 
apoptotic cells by microglia found in demyelinated regions of the brain by interacting with the 
Mertk receptor on microglia as a competitive inhibitor (Figure 4). Preliminary experiments 
conducted by others in the lab demonstrated that APOE can bind to Mertk in an ELISA. APOE2 
and APOE4 were not able to bind to Mertk well; however, APOE3 significantly bound to Mertk. 
Thus, if apoptotic cells were prevented from binding to Mertk by APOE3, this would then inhibit 
efferocytosis and cause the microglia to secrete different factors that would inhibit OPC 
differentiation and thereby inhibit the remyelination of these regions. 
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Figure 4: Proposed APOE inhibition of OPC differentiation mechanism 
APOE3 acts as a competitive inhibitor to the phagocytosis of apoptotic cells in 
demyelinated regions by interacting with the Mertk receptor on microglia. APOE3 appears to 
cause the microglia to secrete factors that inhibit the differentiation of OPCs or prevent the 
production of differentiation factors.  
 
So far only two OPC differentiation assays have been completed and while they show 
similar trends, additional assays will need to be conducted in the future to corroborate the trends 
and verify our findings. Additionally, repeat experiments need to be conducted to corroborate 
the trends of the LFB-PAS staining.  
 In the future, we would like to conduct phagocytosis assays to determine how effectively 
apoe2, apoe3, apoe4 and apoe-/- macrophages ingest apoptotic cells in comparison to WT 
macrophages. This would reveal any differences in macrophage ingestion of apoptotic cells 
across the APOE variants. Additionally, we have collected the supernatants of various apoe 
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mice and conducted proteomics on them. It would be interesting to determine which factors of 
the supernatants promote or inhibit OPC differentiation or the ability of macrophages to 
phagocytose apoptotic cells. 
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